Trials / Recruiting
RecruitingNCT07428044
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
A Phase II Trial of Neoadjuvant Trastuzumab Deruxtecan for Patients With Stage II-III HER2-Amplified or HER2-Mutated Non-Small Cell Lung Cancer (HERCULES)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.
Conditions
- Non-Small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage II
- Non-Small Cell Lung Cancer Stage IIIA
- Non-Small Cell Lung Cancer Stage IIIB
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab Deruxtecan | Trastuzumab deruxtecan (T-DXd, fam-trastuzumab deruxtecan-nxki) is a novel HER2- targeting antibody-drug conjugate (ADC). |
Timeline
- Start date
- 2026-02-13
- Primary completion
- 2027-02-13
- Completion
- 2027-02-13
- First posted
- 2026-02-23
- Last updated
- 2026-02-23
Locations
10 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07428044. Inclusion in this directory is not an endorsement.